Emergence and fast spread of B.1.1.7 lineage in Lebanon.

@inproceedings{Younes2021EmergenceAF,
  title={Emergence and fast spread of B.1.1.7 lineage in Lebanon.},
  author={Manar Younes and Kassem Hamze and Hamed Nassar and Mohamad S. I. Makki and M. Ghaddar and Paul A Nguewa and Fadi Abdel Sater},
  booktitle={medRxiv},
  year={2021}
}
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a rapid spread emerging disease. Recently, a new variant of this virus called SARS-CoV-2 VOC 202012/01 (or B.1.1.7 lineage), described in the United Kingdom (UK), has become highly prevalent in several countries. Its rate of transmission has been estimated to be greatly higher. B.1.1.7 lineage harbors 23 mutations co-existed for the first time in the same variant. Herein, we are interested only by the deletion mutation… 
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
TLDR
Key information is examined and provided on SARS-CoV-2 VOCs, including their transmissibility, infectivity rate, disease severity, affinity for angiotensin-converting enzyme 2 (ACE2) receptors, viral load, reproduction number, vaccination effectiveness, and vaccine breakthrough.
A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America
TLDR
The rapid evolution of SARS-CoV-2 has the potential to allow the newly-emerged B. 1.1.2.7 and P.1-1.1 variants to escape from natural or vaccine-induced neutralizing immunity and viral spreading.
Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America
TLDR
It is strongly suggested that a third dose of vaccine is urgently needed to cover novel variants with affinity scores (equal or less than 70%) to eliminate developing viral mutations and reduce transmission rates.
Lebanese SARS-CoV-2 genomics: 24 months of the pandemic
Intranasal Vaccination Strategy to Control the COVID-19 Pandemic from a Veterinary Medicine Perspective
TLDR
The potential use of intranasal vaccination strategies against human COVID-19, based on a veterinary intranAsal vaccine strategy, is discussed.
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
TLDR
The current extent of genetic change in SARS-CoV-2 is summarised, particularly recently emerging variants of concern are summarized, and the phenotypic consequences of this viral evolution that may impact the future trajectory of the pandemic are considered.
A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR
TLDR
This protocol could be used as a second test to confirm the diagnosis in patients who were already positive to COVID-19 but showed false negative results for S-gene, in case of shortage in sequencing.

References

SHOWING 1-7 OF 7 REFERENCES
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
TLDR
These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and deltaH69/deltaV70 as a broad antibody resistance mechanism against commonly occurring antibody responses to Sars-Cov-2.
The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19
TLDR
The proteins found in the SARS CoV-2 that caused this global pandemic are reviewed to provide a better understanding of the disease.
Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70
  • the COVID-Diagnosis HCL Study Group
    Thermo Fisher's COVID-19 tests: designed with virus mutations in mind
      Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom